Collaboration with OpenAI: Transforming the Way We Work and Innovate Through AI

For over a decade, Moderna has been at the intersection of science, technology and health. Since our beginnings, we’ve leveraged the power of machine learning to support our mission to develop transformative mRNA medicines. The data platform we’ve built over our history helps fuel innovation and positions us well to capitalize on next-generation AI tools. With an ambitious plan to launch multiple products in the next few years, we see AI as a key component to our ability to scale and maximize our impact on patients.

This morning, we announced our ongoing collaboration with OpenAI to co-innovate with a shared vision of AI’s immense potential in the future of business and healthcare. From launching mChat in 2023, our own instance of ChatGPT built on top of OpenAI’s API, to recently deploying OpenAI’s ChatGPT Enterprise across our various business functions, this collaboration will help ensure every employee at Moderna has a purpose-built AI assistant to augment their work with personalized support. To learn more, read the case study about how we’re bringing AI to life across our clinical development, legal and corporate brand teams.

We know successfully embedding AI into our everyday work requires more than technology – it necessitates a strong AI-focused culture. Our emphasis on learning, coupled with our investment in real-time, on-the-job AI training, differentiates us as a digital-first biotechnology company. This commitment is one of the reasons why Moderna was ranked 9th on the 2024 LinkedIn Top Companies List in the United States, as well as 2nd on LinkedIn’s 2024 Top Companies in Healthcare ranking, recognized for our efforts to build a highly skilled, adaptable workforce that is empowered by AI.

We are looking forward to continuing to collaborate with OpenAI and lead the way for AI innovation in our field. Watch the below video to learn more about our work together:

Forward-Looking Statements

This post contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the power of Moderna’s data platform to fuel innovation and Moderna’s ability to capitalize on next-generation AI tools; Moderna’s plan to launch multiple products in the next few years; and Moderna’s ongoing collaboration with OpenAI. The forward-looking statements in this post are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this post in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this post.